June 2013, Vol 4 No 4 - Uncategorized
At the 54th Annual Meeting of the American Society of Hematology, a number of abstracts were presented demonstrating the efficacy and toxicities of bendamustine either alone or in combination with other agents for the treatment of several lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and indolent as well as [ Read More ]
May 2013, Vol 4 No 3 - Uncategorized
The previous articles have outlined the clinical outcomes of clinical trials evaluating bendamustine in chronic lymphocytic leukemia (CLL) and non-HodgÂkin lymphoma (NHL). The third in the series of articles discusses the short-term toxicities of bendamustine from these clinical trials. Patients with CLL are always a challenge to treat due to [ Read More ]
March 2013, Vol 4 No 2 - Uncategorized
The second in a series of 4 articles describes the natural history of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL). As 2 indolent lymphocytic malignancies, they have a similar natural history of a slowly progressive illness that can have progressive cytopenias and/or lymphadenopathy that eventually may require therapy. [ Read More ]
December 2012, Vol 4 No 1 - Uncategorized
Bendamustine has an interesting history that spans more than 50 years. Bendamustine was first synthesized in the early 1960s in the former East Germany. It was first used to treat multiple myeloma and was subsequently extended to patients with chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma. UnfortunateÂly, [ Read More ]
Copyright 2023. The Lynx Group, LLC. All Rights Reserved. Privacy Policy. Sitemap.
